Yakob  Liawatidewi net worth and biography

Yakob Liawatidewi Biography and Net Worth

Jacob Liawatidewi, M.B.A., has served as Executive Vice President of Corporate Administration Center and Sales and Marketing since May 2020, and President of Amphastar France Pharmaceuticals since December 2020 (Amphastar subsidiary), and as Senior Vice President of Corporate Administration Center since March 2014, Corporate Secretary since June 2013, and Senior Vice President of Sales and Marketing since December 2013. Mr. Liawatidewi served as Vice President of Sales and Marketing from August 2012 until his promotion to Senior Vice President. From August 2005 to August 2012, Mr. Liawatidewi was the company’s Associate Vice President of Sales and Marketing. Since joining the company in June 1997 to August 2005, Mr. Liawatidewi held various roles in the company’s business development, sales, and marketing department. Mr. Liawatidewi received a B.S. in Biology from California State University of Fresno in 1996 and an M.B.A. from the National University in 2014.

What is Yakob Liawatidewi's net worth?

The estimated net worth of Yakob Liawatidewi is at least $2.84 million as of August 28th, 2023. Mr. Liawatidewi owns 69,669 shares of Amphastar Pharmaceuticals stock worth more than $2,844,585 as of April 26th. This net worth estimate does not reflect any other assets that Mr. Liawatidewi may own. Learn More about Yakob Liawatidewi's net worth.

How do I contact Yakob Liawatidewi?

The corporate mailing address for Mr. Liawatidewi and other Amphastar Pharmaceuticals executives is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. Amphastar Pharmaceuticals can also be reached via phone at (909) 980-9484 and via email at [email protected]. Learn More on Yakob Liawatidewi's contact information.

Has Yakob Liawatidewi been buying or selling shares of Amphastar Pharmaceuticals?

Yakob Liawatidewi has not been actively trading shares of Amphastar Pharmaceuticals during the past quarter. Most recently, Yakob Liawatidewi sold 28,816 shares of the business's stock in a transaction on Monday, August 28th. The shares were sold at an average price of $53.13, for a transaction totalling $1,530,994.08. Following the completion of the sale, the executive vice president now directly owns 69,669 shares of the company's stock, valued at $3,701,513.97. Learn More on Yakob Liawatidewi's trading history.

Who are Amphastar Pharmaceuticals' active insiders?

Amphastar Pharmaceuticals' insider roster includes Diane Gerst (Director), Richard Koo (Director), Howard Lee (Director), Yakob Liawatidewi (EVP), Mary Luo (COO), Ziping Luo (Chairman), William Peters (CFO), Floyd Petersen (Director), Richard Prins (Director), Michael Zasloff (Director), Jack Zhang (CEO), Yongfeng Zhang (Co-Founder), and Rong Zhou (EVP). Learn More on Amphastar Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amphastar Pharmaceuticals?

In the last year, insiders at the sold shares 28 times. They sold a total of 514,725 shares worth more than $27,557,288.75. The most recent insider tranaction occured on April, 1st when Director Floyd F Petersen sold 500 shares worth more than $21,715.00. Insiders at Amphastar Pharmaceuticals own 27.1% of the company. Learn More about insider trades at Amphastar Pharmaceuticals.

Information on this page was last updated on 4/1/2024.

Yakob Liawatidewi Insider Trading History at Amphastar Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/28/2023Sell28,816$53.13$1,530,994.0869,669View SEC Filing Icon  
4/13/2023Sell11,494$41.56$477,690.6469,215View SEC Filing Icon  
4/10/2023Sell5,000$40.00$200,000.0069,215View SEC Filing Icon  
8/9/2022Sell3,055$39.00$119,145.0061,607View SEC Filing Icon  
7/15/2022Sell10,837$36.64$397,067.6861,607View SEC Filing Icon  
7/15/2021Sell31,524$20.01$630,795.2477,927View SEC Filing Icon  
5/11/2021Sell10,000$19.06$190,600.0071,351View SEC Filing Icon  
7/21/2020Sell5,978$21.22$126,853.1650,182View SEC Filing Icon  
6/9/2020Sell23,405$20.12$470,908.6069,529View SEC Filing Icon  
9/13/2019Sell3,000$21.45$64,350.0033,670View SEC Filing Icon  
9/5/2019Sell1,515$21.24$32,178.6036,670View SEC Filing Icon  
8/13/2019Sell5,000$20.73$103,650.0047,188View SEC Filing Icon  
2/14/2019Sell8,868$23.86$211,590.4839,883View SEC Filing Icon  
2/12/2019Sell4,000$23.70$94,800.0039,883View SEC Filing Icon  
2/5/2019Sell11,397$23.18$264,182.4647,280View SEC Filing Icon  
1/23/2019Sell7,000$22.52$157,640.0040,463View SEC Filing Icon  
1/16/2019Sell3,183$22.15$70,503.4537,471View SEC Filing Icon  
1/14/2019Sell8$22.15$177.2037,471View SEC Filing Icon  
11/30/2018Sell13,980$21.50$300,570.0048,963View SEC Filing Icon  
11/28/2018Sell1,520$20.49$31,144.8037,463View SEC Filing Icon  
11/23/2018Sell1,299$20.26$26,317.7437,463View SEC Filing Icon  
11/9/2018Sell17,808$20.97$373,433.7646,763View SEC Filing Icon  
See Full Table

Yakob Liawatidewi Buying and Selling Activity at Amphastar Pharmaceuticals

This chart shows Yakob Liawatidewi's buying and selling at Amphastar Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amphastar Pharmaceuticals Company Overview

Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Read More

Today's Range

Now: $40.83
Low: $40.39
High: $41.07

50 Day Range

MA: $44.79
Low: $38.65
High: $55.44

2 Week Range

Now: $40.83
Low: $35.62
High: $67.66

Volume

236,143 shs

Average Volume

327,504 shs

Market Capitalization

$2.00 billion

P/E Ratio

15.83

Dividend Yield

N/A

Beta

0.84